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 Background: Kidney transplantation is reported to save costs compared to maintenance dialysis. We analyzed the current 
actual costs of kidney transplantation compared to dialysis, and analyzed risk factors for higher costs after 
transplantation.
 Material/Methods: Altogether, 338 kidney transplant recipients between 2009 and 2014 were included in this study. All individual-
level cost data from specialized health care and data from all reimbursed medication and travel costs were ac-
quired from official records. Cost data were compared before and after transplantation within the same pa-
tients starting from dialysis initiation and continued until the end of follow-up at the end of 2015.
 Results: Total annual costs were median 53 275 EUR per patient in dialysis, 59 583 EUR for the first post-transplanta-
tion year (P<0.001), and 12 045 EUR for the subsequent years (P<0.001 compared to dialysis). Median costs 
for specialized health care were 36 103 EUR/year per patient during dialysis, compared to median 51 640 EUR 
for the first post-transplantation year (P<0.001 compared to dialysis), whereas the median costs for the sub-
sequent years declined to median 4895 EUR/year (P<0.001 compared to dialysis). The median annual costs 
for drug treatments and travel reimbursements during dialysis were higher compared to after transplantation 
(P<0.001). Delayed graft function and highly sensitized status were independent risk factor for higher costs 
during the first the post-transplantation year.
 Conclusions: After the first posttransplant year the costs of a kidney transplant patient for the health care system are <1/3 
of the costs seen during dialysis treatment. Delayed graft function and previous sensitization were associated 
with increased costs post-transplantation.
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Background
In addition to prolonged survival and increased quality of life, 
kidney transplantation has also been associated with signifi-
cant cost savings compared to maintenance dialysis treatment 
in several studies [1–6]. However, comparisons with patients 
who stay on dialysis may be confounded by comorbidities that 
either prevent or delay access to transplantation and may also 
be associated with increased costs. In addition, local health 
care systems and policies greatly influence the costs of both di-
alysis treatment and transplantation. The health care systems 
may also create financial incentives that might affect the tim-
ing of access to the transplant waiting list. For example, insur-
ance coverage has been associated with lower rate of place-
ment on the waiting list and also longer duration of end-stage 
renal disease before wait listing [7,8].
Finland has a universal government health care system fi-
nanced from the national social insurance, and according to 
recent studies the universal health coverage index in Finland 
is among the highest in the world with a very modest total 
health care spending per capita [9,10]. The costs of kidney 
transplantation and dialysis treatment in Finland have been 
analyzed in a study by Salonen et al., including patients receiv-
ing renal replacement therapy during 1991 to 1996 [5]. Several 
changes have occurred during the last years in the treatment 
of dialysis patients, with a higher prevalence of home dial-
ysis modalities, and with more alternatives for the medical 
treatment of complications of end-stage renal disease, such 
as drugs for hyperparathyroidism, hyperphosphatemia, and 
anemia, which are associated with high costs. On the other 
hand, immunosuppressive protocols have remained quite sta-
ble after kidney transplantation with the introduction of ge-
neric immunosuppressive drugs, which may affect the costs 
of kidney transplantation.
The aim of this study was to analyze the current actual costs 
of kidney transplantation compared to dialysis in Finland with 
a Scandinavian setting of universal public health care, and 




Altogether, 338 consecutive patients who received a kidney-
only transplantation from the Helsinki University Hospital 
catchment area between 2009 and 2014 were included. One 
patient who received 2 transplantations during the period 
was excluded from the analyses. Helsinki is the only trans-
plant center in Finland and serves 21 regional hospitals with 
respective nephrology departments and dialysis facilities. After 
the initial post-transplantation period patients return to follow-
up to their regional hospital. Patients included in this study 
were limited to those who had complete follow-up within 
Helsinki University Hospital and all cost data accessible both 
before and after transplantation. This study has the approval 
of both the institutional review board of Helsinki University 
Hospital (326/13/03/002015) and Social Insurance Institution 
of Finland (KELA).
Cost data
Cost analyses were performed from the perspective of the ser-
vice provider and were done using direct costs in each cost 
category. All individual-level cost data from the specialized 
health care were acquired from the hospital billing database 
(ECOMED). Costs were divided in the following categories: 
1) operations, which includes both donor and recipient oper-
ation, travel costs from the organ procurement operation, and 
the costs of the transplantation office; 2) outpatient procedures; 
3) laboratory testing; 4) other diagnostic testing, including ra-
diology, pathology, and clinical physiology; 5) treatment on 
the ward; and 6) outpatient visits, including dialysis sessions.
In addition, individual-level data from all reimbursed medica-
tion and travel costs were acquired from the Social Insurance 
Institution of Finland (KELA). Social insurance covers all the 
costs for prescribed medications that exceed 612.62 EUR per 
year, and additionally 72–100% of the costs of prescription 
medications used for chronic illnesses. For example, diabetes 
medications, immunosuppressive medications, erythropoie-
sis stimulating agents (ESA), and phosphate binders are 100% 
covered by the insurance, whereas medications such as blood 
pressure medications and lipid lowering therapies are 72–75% 
covered. Only medication costs exceeding the deductible were 
included in the analyses.
Travel costs are covered for each patient by the social insur-
ance when the total annual amount of travel costs exceeds 
the deductible, which was 157.20 EUR or 242.25 EUR during 
the study period. Only travel costs exceeding the deductible 
are included in the analyses. Data linkage was done using the 
unique personal identity code as a key.
Annual cost data were compared before and after transplan-
tation from the same patients (i.e. all the patients served as 
their own controls), divided into 365 days periods, with the 
transplant date as the index date. Costs for the specialized 
health care could be calculated for each 365 days after and 
before transplantation, but the data about medication and 
travel costs could only be calculated as mean costs per year 
on the treatment for each patient before and after transplan-
tation, due to the nature of the data received from KELA. Data 
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collection was started from dialysis initiation and continued 
until the end of follow-up at the end of 2015.
Demographic data
The frequency of living donation has been very low in our 
country, and only 4% of the transplantations included in 
the study were from living donors. All the patients were on 
maintenance dialysis before acceptance to the kidney trans-
plant waiting list or before a living donor transplantation. 
Immunosuppression after kidney transplantation was a tri-
ple-drug therapy with cyclosporine or tacrolimus, mycopheno-
late, and steroids. Induction with basiliximab was used only 
in sensitized patients. Immunosuppressive protocol has been 
described in more detail elsewhere [11]. All deceased donors 
were donors after brain death, as donation after circulatory 
death is not used in our country. Cytomegalovirus (CMV) se-
ronegative recipients of an organ from a seropositive donor 
(D+/R–) received 6 months of prophylaxis with valganciclovir 
and were monitored for viremia after the end of prophylaxis; 
other patient groups did not receive antiviral prophylaxis but 
were monitored for CMV viremia after transplantation monthly 
for the first 3 months after transplantation, and treatment was 
initiated in case of symptomatic CMV infection or viral loads of 
1000 IU/mL. Trimethoprim-sulfamethoxazole prophylaxis was 
used for all patients for 6 months after transplantation, or in 
case of allergy, pentamidine inhalations were used instead.
Delayed graft function was defined as the need for dialysis 
during the first week after transplantation. Acute rejections 
were diagnosed with a kidney transplant biopsy according to 
the Banff classification [12]. Clinical data were collected from 
the Finnish Transplant registry, which is a follow-up regis-
try for all transplantation patients in Finland, obliged by law.
Statistical analyses
Differences between 2 groups in continuous variables were 
compared with the Mann-Whitney U test and in categorical 
variables with the Fisher’s exact test. When costs before and 
after transplantation were analyzed, each patients served as 
their own control (i.e., costs during dialysis and after transplan-
tation were compared within the same patient). The nonpara-
metric Friedman test was used for comparisons, as all distribu-
tions were not normal. Univariable and multivariable logistic 
regression was used to analyze risk factors. When analyzing 
risk factors for higher costs during the first year after trans-
plantation, total costs during the first year after transplanta-
tion were divided into quartiles, and the highest cost quar-
tile was the binary outcome variable in the logistic regression 
model. Variables that were significant or close to significant risk 
factors in univariable analyses (P<0.10) were selected to the 
multivariable model. All first-degree interactions were tested 
between the independent significant variables in the multi-
variable model, and no significant interactions were found. 
Calculations were performed with IBM SPSS version 21. Two-
sided P-values <0.05 were considered statistically significant.
Results
Of the 337 patients who received a transplantation and were 
included in the analyses, delayed graft function occurred in 127 
patients (38%), and 5 grafts were lost in the first 2 weeks after 
transplantation, 1 due to venous thrombosis, 2 due to primary 
nonfunction of unknown reason, and 2 due to sudden cardiac 
death. One-year graft survival was 97% and 3-year graft sur-
vival was 92%. The transplantation patients included in the 
study are characterized in Table 1. By the end of the follow-
up at the end of 2015, altogether 42 patients had died, and 
29 patients returned to dialysis.
Mean costs before and after dialysis are depicted in 
Figures 1 and 2. Total annual costs were median 53 275 EUR 




Mean age  52±14
Mean duration of pretransplant 
dialysis (months)
 32±27
Patients with diabetes (%)  79 (23%)
Living donor transplantation (%)  15 (4%)




Number of HLA mismatches
 AB  1.9±0.9
 DR  0.7±0.6
Cold ischemia time (hrs)  19±6
Delayed graft function (%)  127 (38%)
Acute rejection
 T cell-mediated rejection (%)  58 (17%)
 Antibody-mediated rejection (%)  8 (2%)
Patients with positive cPRA before 
transplantation (%) 
 177 (52%)
Patients with cPRA >80% before 
transplantation
 52 (15%)
Table 1. Characterization of the patients included in the study*.
* Mean ±1 SD, unless otherwise indicated, cPRA – calculated 
panel-reactive antibodies.
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(range 14 966 to 232 479 EUR) for the first post-transplanta-
tion year (P<0.001), and 12 045 EUR (range 1787 to 231 112 
EUR) for the subsequent years (P<0.001 compared to dialysis). 
Median annual costs for specialized health care were 36 103 
EUR (range 4618 to 103 007 EUR) per patient during dialysis, 
compared to median 51 640 EUR (range 5337 to 228 128 EUR) 
for the first post-transplantation year (P<0.001 compared to 
dialysis), whereas the median costs for the subsequent years 
declined to median 4895 EUR (range 801 to 183 340 EUR)/year 
(P<0.001 compared to dialysis).
As expected, the most important group of cost savings after 
transplantation were for dialysis visits. During the first post-
transplantation year, costs increased for treatment on the ward, 
surgical operations (mainly the transplantation operation in-
cluding costs for the donor procurement), laboratory tests, and 
diagnostic tests, but declined substantially during the follow-
ing years. The median annual costs for drug treatments during 
dialysis were 10 600 EUR (range 81 to 53 424 EUR), compared 
to 7537 EUR (range 720 to 77 105 EUR) after transplantation 
(P<0.001). Travel costs were significantly higher during dialy-
sis treatment, with median annual cost of 829 EUR (range 7 
to 32 629 EUR) compared to 119 EUR (0 to 14 100 EUR) after 
transplantation (P<0.001).
Table 2 describes the differences in median costs before and 
after transplantation, categorized by clinical variables. Annual 
costs during dialysis treatment were lower in patients on peri-
toneal dialysis (PD) before transplantation compared to he-
modialysis (HD) (P<0.001), and similarly after transplantation 
patients on pretransplant PD had lower annual costs both dur-
ing the first post-transplantation year and later (P=0.005 and 
P=0.02, respectively). During the first post-transplantation 
year, patients with delayed graft function had higher annual 
costs compared to patients with early graft function (P<0.001, 
Figure 3). CMV D+/R– constellation was associated with higher 
costs during the first post-transplantation year compared to 
other patients (P=0.02). No significant differences were seen 
in pre- or post-transplantation costs between patients with 
or without diabetes, highly sensitized patients (maximum 
pre-transplantation cPRA >80), patients receiving living or de-
ceased donor transplantation, patients with acute rejection 
after transplantation, or between patients with cold ischemia 
time below or more than 24 hours, (data not shown).
Results of the univariable and multivariable logistic regression 
analysis of the risk factors for high costs during the first post-
transplantation year (highest quartile, >71 890 EUR per year) 
are shown in Table 3. In univariable analyses, pre-transplan-
tation hemodialysis, delayed graft function, increased donor 
age, highly sensitized status (cPRA >80%), and longer dura-
tion of pre-transplantation dialysis treatment were risk fac-
tors for high costs during the first post-transplantation year. 
Interestingly, CMV serostatus, diabetes, acute rejection, or re-
cipient age were not associated with increased costs. In a mul-
tivariable model including pre-transplantation dialysis modality, 
pre-transplantation dialysis duration, delayed graft function, 
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Diagnostic test (radiology, pathology etc.)
Laboratory tests
Outpatient procedures
Operating room and operations
Treatment on the ward
Dialysis and outpatient clinic
Figure 2.  Costs for specialized health care among 338 patients before and after kidney transplantation, divided into 8 different 
categories: dialysis and outpatient visits, treatment on the ward, operating room and operations (including costs for organ 























Figure 1.  Total mean costs for travel, medication, and specialized 
health care before and after kidney transplantation 
among 338 patients.
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graft function (odds ratio, OR 2.63) and highly sensitized sta-
tus (OR 2.54) were independent significant risk factors for high 
costs during the first post-transplantation year.
Discussion
In this study we compared the current actual costs of main-
tenance dialysis among patients listed for kidney transplan-
tation, and compared these costs with the post-transplanta-
tion costs within the same patients. In addition to the already 
previously shown fact that costs are significantly reduced af-
ter transplantation [4,5], we were able to show in a multivari-
able model that only delayed graft function and highly sensi-
tized status were independent risk factors for high costs after 
transplantation. This has important implications for clinical 
treatment policies, as the frequency of delayed graft function 
can be reduced by actively minimizing the cold ischemia time 
resulting in cost savings. In a recent study from our institution, 
we showed that using peripheral blood lymphocytes instead 
of donor spleen for the prospective cytotoxic crossmatches, 
we were able to significantly reduce cold ischemia times and 
the frequency of delayed graft function [13]. This reduction in 
the frequency of delayed graft function was most pronounced 
in highly sensitized patients, underlying the potential for cost 
savings. In our cohort, induction therapy was used only in sen-
sitized patients, which may also explain the relatively high fre-
quency of delayed graft function, as the occurrence of delayed 
graft function may be lower among patients who receive in-
duction therapy [14].
Patients on PD before transplantation 
(N=124)
Patients on HD before transplantation 
(N=214)
Median annual costs during dialysis  51383 (26403–107571)*  54137 (26019–119913)*
Median costs for the 1st posttransplant year  56136 (18131–165348)**  62285 (14966–232479)**
Median costs for later posttransplant year  11117 (4978–231112)***  12797 (1787–194078)***
Patients with DGF 
(N=128)#
Patients with no DGF 
(N=205)
Median annual costs during dialysis  55423 (27278–119913)  51578 (26019–107571)
Median costs for the 1st posttransplant year  68374 (36604–232479)*  55200 (14966–183101)*
Median costs for later posttransplant year  11995 (2387–81419)  11977 (1787–231112)
CMV D+/R– patients 
(N=72)
Other CMV combinations 
(N=266)
Median annual costs during dialysis  50782 (26019–98097)  53483 (26403–119913)
Median costs for the 1st posttransplant year  65105 (34887–232479)***  58151 (14966–216404)***
Median costs for later posttransplant year  12798 (1787–231112)  11924 (1893–87996)
Patients with aRX 
(N=65)
Patients with no aRX 
(N=273)
Median annual costs during dialysis  53765 (26403–103336)  53152 (26019–119913)
Median costs for the 1st posttransplant year  64571 (36604–158356)  58430 (14966–232479)
Median costs for later posttransplant year  12492 (2605–194078)  11995 (1787–231112)
Living donor transplantation 
(N=15)
Deceased donor transplantation 
(N=323)
Median annual costs during dialysis  56269 (41990–73099)  53237 (26019–119913)
Median costs for the 1st posttransplant year  48807 (39668–183101)  59902 (14966–232479)
Median costs for later posttransplant year  10655 (6925–50735)  12132 (1787–231112)
Table 2.  Comparison of total costs (in euros) pre and posttransplantation between different patient groups, expressed as median 
(range).
PD – peritoneal dialysis; HD – hemodialysis; DGF – delayed graft function; aRX – acute rejection. * P<0.001; ** P=0.005; *** P=0.02; 
# Five patients with no graft function excluded.
397
Helanterä I. et al.: 
Current costs of kidney transplantation
© Ann Transplant, 2019; 24: 393-400
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Several other studies have analyzed the impact of clinical vari-
ables on higher costs after transplantation. Lower renal func-
tion has been associated with increased costs after transplan-
tation in multiple studies [15,16]. Similarly, post-transplantation 
complications, such as CMV and acute rejection have been 
associated with increased costs [17], although these findings 
could not be confirmed in our current analysis. In a study by 
Hagenmeyer et al., delayed graft function was similarly asso-
ciated with higher costs after transplantation [17]. This study, 
however, included patients transplanted between 1998 and 
2000, and excluded the costs for organ procurement, pre-trans-
plantation care, and transplantation surgery, and did not have 
access to actual medication costs. In addition, only a limited 
number of variables was used for multivariable modelling. Our 
study, on the other hand, describes the current direct costs after 
transplantation, with access to pre- and post-transplantation 
data used for adjustment in the multivariable models. The def-
inition of delayed graft function in our current study was the 
need for dialysis treatment during the first post-transplanta-
tion week. This definition is one of the most commonly used 
definitions in the literature and the only definition recorded 
in our transplant registry, but has several limitations based 
on the subjective clinical decision of the need for dialysis, and 
probably does not accurately describe all patients with com-
promised initial graft function. In addition, although multi-
variable model was adjusted for donor age and cold ischemia 
time, other unidentified characteristics related to the donor 
organ quality or recipient may confound our findings of the 
increased costs associated with delayed graft function itself.
Several previous studies have compared the costs of dialy-
sis and transplantation [4-6], and our findings are in line with 
these previous studies. Comparison of actual costs is very dif-
ficult between different countries and health care systems, 
and major differences can be seen between countries in total 
spending for health care [10], which probably also has impli-
cations for the costs of pre- and post-transplantation care of 
patients with end-stage renal disease. Costs of dialysis and 
kidney transplantation were compared earlier in a Finnish 
study by Salonen et al. [5]. The material for their study de-
rived from 1991 to 1996, and in addition, many costs were es-
timates or theoretical costs, and not all actual cost data were 
available for this earlier study. In a recent study from Sweden, 
Jarl et al. used a similar setting to our study and compared 
the costs of the same patients before and after transplanta-
tion [4]. According to the calculations in the Jarl et al. study, 
Univariable OR 95% CI P Multivariable OR 95% CI P
Hemodialysis before transplantation 2.22 1.23–3.98 0.005 1.48 0.79–2.77 0.22
Delayed graft function 3.49 2.16–5.63 <0.001 2.63 1.55–4.48 <0.001
Diabetes 1.70 0.98–2.96 0.06 1.52 0.84–2.75 0.17
Cold ischemia time (hrs) 1.01 0.96–1.05 0.73
Acute rejection 1.37 0.83–2.25 0.22
CMV D+/R– status 1.57 0.89–2.78 0.12
Living donor transplantation 1.11 0.34–3.57 0.87
cPRA >80% 2.40 1.29–4.46 0.006 2.54 1.29–4.99 0.007
Recipient age (yrs) 0.99 0.98–1.02 0.82
Donor age (yrs) 1.02 1.01–1.04 0.05 1.01 0.99–1.03 0.37
Duration of pretransplant dialysis 
(months) 
1.01 1.00–1.02 0.001 1.01 0.99–1.02 0.08
Table 3.  Univariable and multivariable logistic regression analysis of the risk factors for high costs (highest quartile) during the first 




























Figure 3.  Comparison of total costs (in euros) during the first 
posttransplant year between patients with delayed 
graft function (DGF) and early graft function after 
kidney transplantation. Error bars represent 1 standard 
deviation.
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cost savings of 380 000 EUR per patient for a 10-year period 
could be obtained with a transplantation. Our findings of the 
magnitude of the cost savings are in a similar range, although 
our data enabled detailed analysis only from the first post-
transplantation years, and not from long-term costs.
In the current study, peritoneal dialysis was associated with 
lower costs both during dialysis treatment and after transplan-
tation. However, in a multivariable model dialysis modality was 
not a significant predictor of higher costs after transplanta-
tion, suggesting that other factors, such as younger age, fewer 
comorbidities, and lower frequency of delayed graft function 
among the patients in PD before transplantation explain the 
lower post-transplantation costs. Further analysis of the cost 
differences during dialysis treatment was outside the scope 
of the current study. In general dialysis treatment, especially 
peritoneal dialysis, was associated with lower annual costs 
compared to the first post-transplantation year, suggesting 
that the short-term economic benefit of transplantation may 
be questioned in patients with high risk of complications and 
mortality early after transplantation, such as elderly patients.
This study has some limitations of note. No cost data for pri-
mary health care were available for this study. However, most 
of the contacts to health care after transplantation during the 
first years are to specialized health care, and the effect is likely 
low during the first years after transplantation. Only direct 
costs were available for this study, and no information about 
disability or loss of income was available for the current study. 
Employment rate among end-stage renal disease patients is 
generally low in our population according to our recent study, 
and is not significantly higher after transplantation compared 
to peritoneal dialysis or home hemodialysis [18]. In addition, 
we did not have access to exact costs for each year regarding 
medications and travel costs, but the cost estimates are based 
on average costs per year per treatment modality. Presumably 
medication costs for the first post-transplantation year would 
be higher compared to later years (due to higher doses and 
trough level targets of immunosuppressive drugs), and as we 
used the mean costs during all the post-transplantation years, 
cost savings seen in medication costs during later years af-
ter transplantation compared to dialysis are likely even larger 
than we report. Medications given in the hospital are included 
in the costs of the treatment on the ward, reducing the pos-
sible bias. On the other hand, all these aforementioned limi-
tations would presumable result in lower relative costs after 
transplantation compared to dialysis and our analyses likely 
underestimate the cost savings of kidney transplantation com-
pared to dialysis. In addition, our cohort included only patients 
from the Helsinki metropolitan area, which is the most densely 
populated part of Finland, and travel costs would probably be 
much higher in rural areas with long distances to dialysis facil-
ities, which similarly probably underestimates the travel cost 
savings achieved with a kidney transplantation. The strength of 
our study is a relatively large sample of kidney transplantation 
patients with individual-level actual cost data available from 
both pre- and post-transplantation period, and with multiple 
clinical factors available for analyzing risk factors for higher 
costs after transplantation.
Conclusions
In conclusion, the current costs in Finland for the first post-
transplantation year exceed the costs of dialysis treatment, 
but in the subsequent years the costs of a kidney transplan-
tation patient for the health care system are <1/3 of the costs 
seen during dialysis treatment. Cost savings are seen in all cat-
egories in the long-term, including costs for medications and 
travel costs. Highly sensitized patients and patients with de-
layed graft function are at the highest risk for increased costs 
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